Molecular Health to collaborate with FALCO biosystems
Molecular Health GmbH announced today that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd. to provide
genetic analysis services using MH Guide/BRCA and
MH Guide/Mendel.
Data can change how your organization approaches healthcare. Improve clinical decisions by harnessing molecular data – and become a key player in precision medicine.
With increasing health issues all over the world and the need for faster and cheaper drug development, it is necessary to start leveraging the vast data ocean of life sciences. Bringing together AI with predictive analytics and real-world data (RWD) is where it might be game changing: Predicting the success of clinical trials can redirect the focus of pharma and biotech companies onto compounds with the most potential, bringing drugs faster to the patients who need them.
Molecular Health GmbH announced today that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd. to provide
genetic analysis services using MH Guide/BRCA and
MH Guide/Mendel.
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy.
BRCA1/2 variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition.
Klicken Sie auf den unteren Button, um den Inhalt von www.linkedin.com zu laden.
MOLECULAR HEALTH DATAOME has become one of the largest globally available resources of clinico-molecular data and knowledge. From millions of patient lives to hundreds of billions of molecular data points, it provides a single point of access to the world’s biomedical knowledge through our decision support applications.
Molecular Health Predict (MH Predict) is an application to predict clinical trials probabilities of success. It enables the improvement of clinical trial success and reduces clinical trial failure while optimizing resource allocation for the biopharma industry and investors and enhancing the overall efficiency of drug development.
Molecular Health Guide Mendel (MH Mendel) supports human geneticists in diagnosing hereditary diseases and creating diagnostic reports for individuals. The germline data analysis follows official genetic guidelines and uses the latest, world known ACMG variant classification criteria.
Molecular Health Guide (MH Guide) identifies safe and effective medication for cancer patients by analyzing the cancer’s molecular profile. It matches detected tumor mutations to the world’s knowledge in the field of oncology and helps medical experts to create a patient-specific clinical report with treatment recommendations.
Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants for hereditary breast and ovarian cancer. It creates individual patient reports based on NGS data from BRCA1/BRCA2 and other associated genes following official genetic guidelines.
Molecular Health’s growing number of customers and partnerships include some of the best hospitals, laboratories, universities, and genetic facilities in the world.
Call us for a product demo and to calculate the Return on Investment you can expect.
Phone: +1 346-221-1955
E-mail: CustomerCareUS@molecularhealth.com